This website is for UK Healthcare Professionals only

Expert Perspectives Video Series

AbbVie presents this series of Clear Horizons videos on RINVOQ in atopic dermatitis. Watch the trailer below


Hear from dermatology experts across the UK
on the following topics:

Where are we now in atopic dermatitis (AD)?

Dr Andrew Pink, Consultant Dermatologist at St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust

RINVOQ mode of action in AD 

Dr Andrew Pink, Consultant Dermatologist at St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust

Clinical overview of RINVOQ: MEASURE UP 1 and 2

Dr Hamish Hunter, Consultant Dermatologist at Salford Royal NHS Foundation Trust

HEADS UP trial overview

Dr Ben Walker, Consultant Dermatologist at Harrogate and District NHS Foundation Trust

RINVOQ for treating AD in adolescents

Dr Jen Sharif, Consultant Dermatologist, Salford Royal NHS Foundation Trust

AD UP: clinical efficacy and safety of RINVOQ + TCS

Dr Ben Walker, Consultant Dermatologist at Harrogate and District NHS Foundation Trust

Initiating Therapy

Dr Eirini Merika, Consultant Dermatologist at Chelsea and Westminster Hospital, London

The Impact of AD: Patient Stories

Teena Mackenzie, Biologic, Inflammatory Disease and Research CNS at Royal Berkshire Hospital and Oxford University Hospitals NHS Trust

1. RINVOQ Summary of Product Characteristics

UK-RNQD-220108. Date of preparation: May 2022

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. 
Adverse events should also be reported to AbbVie on GBPV@abbvie.com